Becton, Dickinson and Company (BD) has launched the new third-generation BD Kiestra Total Lab Automation System for microbiology laboratories.
The robotic track system is suitable for use with the BD Kiestra microbiology laboratory solution, which automates lab specimen processing.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed to meet the evolving requirements of labs, the new robotic track system will enable the formation of a custom and flexible total lab automation configuration that can link several BD Kiestra modules.
By using multiple track options and instruments, labs can select their automation entry point and configure the system to meet their individual workflow and physical lab requirements.
The workflow can be completely automated, from routine specimen inoculation processes to advanced incubation, imaging and colony selection for the detection of pathogens.
Using BD Synapsys informatics solution, each step of the lab’s diagnostic pathway can be traced. The solution will help improve laboratory decision-making and productivity through integrated workflows and on-demand insights.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBD Microbiology vice-president and general manager Cecilia Soriano said: “The track-based configuration options are designed to eliminate the manual sorting of plates and walking the specimen from module to module, which helps to ensure culture integrity and results in streamlined workflows.
“The modular tracks use a sophisticated robotic highway on/off ramp design to help eliminate bottlenecks, traffic jams and plate collisions.”
BD Kiestra lab solutions, including scalable and modular microbiology workflow automation solutions, offer total lab automation for the clinical microbiology laboratory.
In another recent development, BD and CerTest Biotec received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for their molecular assay to detect the Mpox virus.
